Starpharma has announced the signing of a UK sales and distribution agreement for its Viraleze astodrimer sodium antiviral nasal spray with LloydsPharmacy and its parent company McKesson, with LloydsPharmacy set to launch the nasal spray on its web site within a week and in its stores sometime in April 2021. Viraleze was approved for sale in the UK and in Europe in February 2021. According to Starpharma, studies conducted at the Scripps Research Institute demonstrated that Viraleeze (SPL7013) inactivated almost 100% of SARS-CoV-2 virus within a minute.
Starpharma CEO Jackie Fairley commented “We are excited that Viraleze will be available from next week in the second largest pharmacy chain in the UK. The LloydsPharmacy/McKesson team shares Starpharma’s enthusiasm and commitment to bring Viraleze antiviral nasal spray to UK consumers as they emerge from their latest lockdown. LloydsPharmacy represents an ideal partner for this product.”
LloydsPharmacy Head of e-Commerce and Category ManagementJohn Acland said, “We are excited to have secured exclusive rights to Viraleze for the UK. It is a highly innovative product with compelling customer benefits and is well supported by an impressive body of quality science and research. We hope Viraleze will bring LloydsPharmacy customers added peace of mind and protection as we enter the next chapter of the pandemic and re-emerge back into work, school and social settings.”
Read the Starpharma press release.
